ArticleAnnals of medicine and surgery (2012)2020
Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease.
Article in Annals of medicine and surgery (2012), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- A systematic review and meta-analysis of glucocorticoids treatment in severe COVID-19: methylprednisolone versus dexamethasone.BMC infectious diseases · 2023Pooled it
- High-Dose versus Low-Dose Corticosteroids in COVID-19 Patients: a Systematic Review and Meta-analysis.Journal of cardiothoracic and vascular anesthesia · 2022Pooled it
- Methylprednisolone pulse therapy compared with intravenous dexamethasone for severe COVID-19 patients: a randomized clinical trial.Virology journal · 2025Trial
- Comparison of the efficacy of equivalent doses of dexamethasone, methylprednisolone, and hydrocortisone for treatment of COVID-19-related acute respiratory distress syndrome: a prospective three-arm randomized clinical trial.Wiener medizinische Wochenschrift (1946) · 2023Trial
- Comparison of the effect of intravenous dexamethasone and methylprednisolone on the treatment of hospitalized patients with COVID-19: a randomized clinical trial.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Trial
- A High-Dose Corticosteroid Treatment Increases Coronavirus Disease of 2019 Mortality in Intensive Care Units.Turkish journal of pharmaceutical sciences · 2024Article
- Comparative Efficacy of Inhaled and Intravenous Corticosteroids in Managing COVID-19-Related Acute Respiratory Distress Syndrome.Pharmaceutics · 2024Article
- Evaluation of the use of methylprednisolone and dexamethasone in asthma critically ill patients with COVID-19: a multicenter cohort study.BMC pulmonary medicine · 2023Article
- Review
- Clinical effect of early administration of tocilizumab following the initiation of corticosteroid therapy for patients with COVID-19.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2022Article
- Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment.Process biochemistry (Barking, London, England) · 2022Article
- A Retrospective Study to Compare the Effects of Methylprednisolone and Dexamethasone in 35 Patients with Anaphylactic Shock Due to Iodinated Contrast Media During Cardiac Catheterization.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- PEGylated green halloysite/spinel ferrite nanocomposites for pH sensitive delivery of dexamethasone: A potential pulmonary drug delivery treatment option for COVID-19.Applied clay science · 2022Article
- Corticosteroids use for COVID-19: an overview of systematic reviews.Le infezioni in medicina · 2022Review
- Role of Dexamethasone and Methylprednisolone Corticosteroids in Coronavirus Disease 2019 Hospitalized Patients: A Review.Frontiers in microbiology · 2022Review
- Immune response and potential therapeutic strategies for the SARS-CoV-2 associated with the COVID-19 pandemic.International journal of biological sciences · 2022Review
- Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammationTurkish journal of medical sciences · 2021Review
- Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP).Infectious diseases and therapy · 2021Article
- Dexamethasone or methylprednisolone therapy in covid-19 pneumonia: A retrospective and comparative study of 513 cases.Annals of medicine and surgery (2012) · 2021Article
- Impact of intermediate to high doses of methylprednisolone on mortality rate in patients with COVID-19 pneumonia-induced severe systemic inflammation.International journal of clinical practice · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe first case of Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were diagnosed in Wuhan, China in 2019. In the first half of 2020 this disease has already converted into a global pandemic. Various treatment options were being tried all over the world. Some studies showed beneficial effects of corticosteroids in covid 19. Hence, we designed this study to compare the effect of two steroids in moderate to severe covid 19 disease.
objectivesTo compare the efficacy and safety of dexamethasone and methylprednisolone in moderate to severe covid 19 disease. STUDY SETTINGS: Fatima Memorial Hospital, Lahore and Ganga Ram hospital, Lahore. STUDY
designQuasi experimental, interventional study. DURATION OF STUDY: From 1st June 2020 to 30th June 2020. METHODOLOGY:
resultsThe mean age of patients was 57.91 years in dexamethasone group and 54.86 years in methylprednisolone group. In dexamethasone group, there were 15 (42.8%) critically ill patients who were shifted to Intensive care unit (ICU) and seven (20%) of them needed ventilatory support, whereas in methylprednisolone group 22 (33.8%) had to be admitted in ICU with eight (12.3%) patient needing ventilator. As outcome measure, patients in both the groups showed marked improvement in temperature, oxygen requirement and C-reactive protein (CRP) on day 5. Only six (17.1%) patient died who received dexamethasone while 10 (15.3%) patients died among those receiving methylprednisolone.
conclusionDexamethasone and methylprednisolone both are equally effective in treating moderate to severe covid 19 disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.